Can an oral chemo pill boost immunotherapy's power against lung cancer?

NCT ID NCT02546986

Terminated Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding an oral chemotherapy drug (CC-486, a form of azacitidine) to the immunotherapy pembrolizumab can help people with advanced non-small cell lung cancer who have already received one round of platinum-based chemotherapy. About 100 participants will be randomly assigned to receive either the combination or pembrolizumab alone. The study aims to see if the combination delays cancer progression better than the standard single-drug approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an oral chemotherapy drug called CC-486 (azacitidine) combined with the immunotherapy pembrolizumab
What this could lead to: If the combination works better than pembrolizumab alone, it could offer a new treatment option for people with advanced lung cancer who have already tried chemotherapy.
What could go wrong: This is a phase 2 trial, so results are still preliminary. Adding CC-486 may increase side effects without improving outcomes, and the benefit may be limited to certain patient subgroups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Show contact details

Locations

Georgetown University Medical Center

Washington D.C., District of Columbia, 20057, United States
Local Institution - 006

New York, New York, 10011, United States
Local Institution - 200

Marseille, 13915, France
Local Institution - 201

Villejuif, 94805, France
Local Institution - 203

Toulouse, 31059, France
Local Institution - 204

Lyon, 69008, France
Local Institution - 300

Esslingen am Neckar, 73730, Germany
Local Institution - 301

Löwenstein, 74245, Germany
Local Institution - 302

Berlin, State of Berlin, 13125, Germany
Local Institution - 304

Cologne, 50937, Germany
Local Institution - 600

Novara, 28100, Italy
Local Institution - 601

Aviano, 33081, Italy
Local Institution - 602

Milan, 20132, Italy
Local Institution - 603

Napoli, Campania, 80131, Italy
Local Institution - 604

Catania, 95122, Italy
Local Institution - 605

Roma, 00128, Italy
Local Institution - 606

Milan, 20133, Italy
Local Institution - 700

Valencia, 46014, Spain
Local Institution - 701

Madrid, 28040, Spain
Local Institution - 702

Barcelona, 08035, Spain
Local Institution - 703

Madrid, 28034, Spain
Local Institution - 704

Madrid, 28040, Spain
Local Institution - 705

Barakaldo, 48903, Spain
Local Institution - 706

Madrid, 28041, Spain
Local Institution - 903

Athens, 15562, Greece
NYU Langone Medical Center

New York, New York, 10016, United States
North Shore Hematology Oncology Associates

East Setauket, New York, 11733-3456, United States
Palo Verde Hematology Oncology

Glendale, Arizona, 85304, United States
Research Medical Center

Kansas City, Missouri, 64132, United States
UCLA Hematology Oncology

Los Angeles, California, 90095, United States
University Cancer and Blood Center, LLC

Athens, Georgia, 30607, United States
Vanderbilt Univ Medical Center

Nashville, Tennessee, 37232-6307, United States
Washington Univ School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.